Table 1.
Demographics and key characteristics of participants.
| Aβ−/Ast− (n = 557) | Aβ−/Ast+ (n = 165) | Aβ+/Ast− (n = 186) | Aβ+/Ast+ (n = 108) | |
|---|---|---|---|---|
| Age, mean (SD) | 68.2 (8.6) | 72.1 (8.2)a | 68.6 (7.6)b | 74.7 (10.6)a,c |
| Sex, n (% female) | 367 (65.9) | 137 (83.0)a | 122 (65.6)b | 79 (73.1) |
| MMSE/MoCA, mean (SD) | 28.1 (3.3)/27.5(1.8) | 28.1 (3.2)/28.1(1.7) | 27.8 (3.2)/26.7(4.1)b | 27.1 (6.1)/27.2(1.4) |
| APOE e4 (% of carriers) | 89 (16.0) | 25 (15.2) | 33 (17.7) | 25 (23.1) |
| Education, years (SD) | 15.0 (2.7) | 15.2 (3.1) | 14.8 (2.7) | 15.0 (2.8) |
| Aβ burden (z-score) | −0.52 (0.65) | −0.40 (0.57) | 1.17 (0.63)a,b | 1.25 (0.69)a,b |
| Plasma GFAP (z-score) | −0.50 (0.51) | 1.20 (0.75)a | −0.42 (0.52)b | 1.48 (0.88)a-b,c |
| Plasma p-tau181 (z-score) | −0.12 (0.90) | 0.10 (0.82)a | −0.14 (0.97) | 0.77 (1.89)a,b,c |
| Plasma p-tau231 (z-score) | −0.03 (1.00) | −0.12 (0.82) | −0.04 (0.86) | 0.55 (1.26)a,b,c |
| Plasma p-tau217 (z-score) | −0.27 (0.38) | −0.24 (0.38) | 0.17 (0.49) | 1.12 (1.99)a,b,c |
| Plasma NfL (z-score) | −0.24 (0.62) | 0.42 (0.99)a | −0.13 (1.22)b | 0.80 (1.47)a,b,c |
Abbreviations: Aβ: Amyloid-β; Aβ: Aβ-negative; Aβ+: Aβ-positive; Ast−: reactive astrocyte negative; Ast+: reactive astrocyte positive; APOE e4: Apolipoprotein ε4; MMSE: Mini-Mental State Exam; MoCA: Montreal Cognitive Assessment; GFAP: glial fibrillary acidic protein; NfL: neurofilament light chain; p-tau: phosphorylated tau.
a =
different from Aβ−Ast−,
b =
different from Aβ−/Ast+,
c =
different from Aβ+/Ast−.
Missing APOE e4: 140 Aβ−/Ast−, 43 A-/Ast+, 45 Aβ+/Ast−, 17 Aβ+/Ast+.Missing NfL: 2 Aβ−/Ast−, 2 Aβ−/Ast+, 1 Aβ+/Ast−. Plasma p-tau231 is available for a subset of participants from TRIAD and Pittsburgh cohorts. Plasma p-tau217 is available for a subset of participants from TRIAD cohort.